Deletion of ALKBH5 can sensitize tumors to anti-PD-1 therapy, reduce tumor growth, and prolong mouse survival during GVAX/anti-PD-1 treatment by inhibiting the composition of tumor-infiltrating Tregs and MDSCs in vitro and in vivo, while melanoma patients harboring ALKBH5 deletion/mutation are more sensitive to anti-PD-1 therapy (Li et al., 2020c). The gene discussed is ALKBH5; the disease is melanoma.